Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients. Founded by George Hillman, George Stamatoyannopoulos, Ivor Royston, and Ronald Berenson in 2016, Viracta Therapeutics is backed by investors that include Aberdare Ventures, Lilly Ventures, NantKwest, Taiwania Capital, and Wicklow Capital and is headquartered in San Diego.